Chandra Bhagat Pharma Ltd
₹ 49.9
-4.95%
14 Aug
- close price
About
Incorporated in 2003, Chandra Bhagat Pharma Ltd manufactures chemical and pharmaceutical products.[1]
Key Points
- Market Cap ₹ 37.6 Cr.
- Current Price ₹ 49.9
- High / Low ₹ 55.0 / 29.7
- Stock P/E 12.3
- Book Value ₹ 43.9
- Dividend Yield 0.00 %
- ROCE 12.1 %
- ROE 9.67 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 1.14 times its book value
- Promoter holding has increased by 0.83% over last quarter.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 10.5% over past five years.
- Company has a low return on equity of 5.92% over last 3 years.
- Earnings include an other income of Rs.3.35 Cr.
- Company has high debtors of 171 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61 | 80 | 90 | 97 | 106 | 94 | 71 | 94 | 120 | 221 | 89 | 116 | |
| 58 | 76 | 85 | 92 | 102 | 91 | 67 | 91 | 116 | 228 | 88 | 112 | |
| Operating Profit | 3 | 3 | 4 | 5 | 5 | 3 | 4 | 3 | 3 | -7 | 1 | 4 |
| OPM % | 4.9% | 4.3% | 4.9% | 4.7% | 4.3% | 3.3% | 5% | 3.0% | 2.8% | -3.2% | 0.7% | 3.3% |
| 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 11 | 3 | 3 | |
| Interest | 2 | 3 | 4 | 4 | 4 | 3 | 4 | 3 | 2 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 4 |
| Tax % | 39% | 51% | 27% | 33% | 22% | 26% | 32% | 27% | 22% | 33% | 26% | 26% |
| 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 3 | |
| EPS in Rs | 10.29 | 8.37 | 15.79 | 24.64 | 10.29 | 0.41 | 0.25 | 1.06 | 1.21 | 2.03 | 1.14 | 4.04 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 10% |
| 3 Years: | -1% |
| TTM: | 31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 74% |
| 3 Years: | 50% |
| TTM: | 330% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -12% |
| 3 Years: | -29% |
| 1 Year: | -10% |
| Return on Equity | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 5% |
| 3 Years: | 6% |
| Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.42 | 0.42 | 0.42 | 0.42 | 0.67 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 6 | 6 | 7 | 8 | 14 | 18 | 18 | 19 | 20 | 21 | 22 | 26 |
| 28 | 28 | 22 | 22 | 31 | 30 | 27 | 21 | 19 | 16 | 21 | 17 | |
| 8 | 10 | 26 | 28 | 37 | 19 | 19 | 25 | 14 | 56 | 51 | 45 | |
| Total Liabilities | 42 | 44 | 56 | 58 | 83 | 75 | 72 | 72 | 61 | 102 | 102 | 94 |
| 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 3 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 5 | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| 41 | 44 | 51 | 56 | 78 | 74 | 71 | 72 | 60 | 99 | 99 | 90 | |
| Total Assets | 42 | 44 | 56 | 58 | 83 | 75 | 72 | 72 | 61 | 102 | 102 | 94 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | -9 | -6 | 4 | -7 | 8 | 12 | 5 | 6 | -6 | 9 | |
| 0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | -0 | -2 | -1 | -0 | |
| 0 | 0 | 8 | 7 | -4 | 7 | -6 | -10 | -4 | -6 | 2 | -6 | |
| Net Cash Flow | 0 | 0 | -1 | -0 | -0 | -0 | 2 | 3 | 1 | -1 | -4 | 2 |
| Free Cash Flow | 0 | 0 | -9 | -6 | 4 | -7 | 8 | 12 | 5 | 4 | -6 | 8 |
| CFO/OP | 0% | 0% | -200% | -129% | 98% | -238% | 229% | 440% | 164% | -94% | -805% | 250% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 71 | 66 | 80 | 67 | 90 | 54 | 80 | 58 | 25 | 65 | 148 | 171 |
| Inventory Days | 177 | 123 | 133 | 145 | 174 | 187 | 215 | 153 | 100 | 15 | 3 | 18 |
| Days Payable | 43 | 33 | 81 | 69 | 117 | 53 | 79 | 12 | 11 | 23 | 45 | 124 |
| Cash Conversion Cycle | 205 | 156 | 132 | 143 | 146 | 188 | 216 | 199 | 114 | 57 | 107 | 65 |
| Working Capital Days | 166 | 134 | 125 | 138 | 83 | 148 | 177 | 104 | 75 | 36 | 101 | 77 |
| ROCE % | 10% | 10% | 15% | 17% | 13% | 7% | 7% | 9% | 7% | 8% | 6% | 12% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Export of Goods (FOB basis) INR Lakhs |
|
||||||
| Number of permanent employees count |
|||||||
| Export Revenue Share (Export % of Revenue from Operations) % |
|||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Corrigendum Of AGM Notice
- Corrigendum to AGM notice updates link for 66 lakh convertible warrants compliance certificate before 1 Sept 2026 AGM.
-
Notice Of Shareholders Meeting Scheduled On 1St September, 2026
- AGM on 1 Sep 2026; seeks capital hike to Rs 15 crore and 66 lakh warrants at Rs 44.
- Reg. 34 (1) Annual Report.
-
Board Meeting Outcome for For Approval Of Preferential Issue And Other Agenda
- Board approved authorised capital increase and 66 lakh warrants issue worth Rs 29.04 crore, AGM on Sept 1, 2026.
-
Board Meeting Intimation for Fund Raising Through Preferential Issue.
- Board meets 5 Aug 2026 to increase authorised capital and consider preferential fund raising.
Business Overview:[1][2]
a) CBPL, under the brand name CBC, is engaged in manufacturing pharmaceutical formulations such as intravenous (IV) and intramuscular (IM) injections, tablets, and capsules
for both domestic and international markets.
b) The company operates primarily through contract manufacturing and job work arrangements, while maintaining
a diversified product portfolio across a multiple therapeutic segments including oncology, antibiotics, anesthesia, hormones, orthopedics, cardiology, nephrology, neurology, pediatrics, antifungal, and antiviral treatments.
c) In addition to formulations, CBPL is actively involved in the ethical promotion and marketing of Active Pharmaceutical Ingredients (APIs), specialty chemicals, and intermediates, leveraging its own distribution network and sales force.
d) Its major focus lies in supplying critical disease treatments—particularly injections, tablets, and capsules—to hospitals, healthcare centers, government institutions, NGOs, and distributors, combining sourcing, marketing, supply of both generic and branded medicines with a presence in domestic and international markets.